Document is current
Any future updates will be listed below
-
Authors
Sumiyoshi, Issei
Togo, Shinsaku
Watanabe, Junko
Kaneko, Izumi
Uzu, Seiji
Yonekura, Toshiya
Komatsu, Tomoya
Kato, Motoyasu
Nakazawa, Shun
Motomura, Hiroaki
Ochi, Yusuke
Kadoya, Kotaro
Ihara, Hiroaki
Hoshi, Kazuaki
Kitamura, Hideya
Ogura, Takashi
Takahashi, Kazuhisa
-
Funding
Funding for this research was provided by:
EXORPHIA, INC.
Japan Society for the Promotion of Science (21K16122, 23K15196, 24K19116)
- License Information
-
More Information
Article History
Received: 15 January 2025
Accepted: 22 July 2025
First Online: 15 August 2025
Declarations
:
: The use of human-derived fibroblasts was approved by the Institutional Review Board of Juntendo University School of Medicine and Kanagawa Cardiovascular and Respiratory Center under the title"Functional analysis of lung fibroblasts in interstitial pneumonia/pulmonary fibrosis"with approval number 2012173, granted on January 21, 2013. This study was conducted and reported in accordance with the ARRIVE guidelines 2.0 to ensure rigorous and reproducible animal research. All animal experiments were approved by the Institutional Animal Care and Use Committee of SMC Laboratories, Inc. for the study titled"Efficacy evaluation of Compound in a bleomycin-induced pulmonary fibrosis mouse model"(approval no. B060, approved on July 21, 2020), and by the Animal Experiment Committee of Juntendo University School of Medicine for the study titled"Efficacy evaluation of extracellular vesicles derived from mesenchymal stem cells in a bleomycin-induced pulmonary fibrosis mouse model"(Approval No. 2023170, approved on April 1, 2023). This study utilized the HFL1 human lung fibroblast cell line (ATCC, CCL-153) and Human Mesenchymal Stem Cells (HMSCs) purchased from ATCC (Manassas, VA, USA) and Lonza (Walkersville, MD, USA), respectively. According to the information provided by both suppliers, the derivation of these cell lines was conducted with appropriate ethical approval, and informed consent was obtained from the donors. Detailed ethical compliance information can be found in the documents provided by the suppliers, which are included as supplementary files.
: Written informed consent was obtained from all subjects who participated in this study.
: IK, SU, TY, and TK are employees of EXORPHIA, INC., which provided funding and contributed to the study design, data analysis, and manuscript preparation. All authors declare that they have no additional financial or non-financial competing interests.
